Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors

被引：8

作者：

Dashora, Umesh ^{[1
]}

Gallagher, Alison ^{[2
]}

Dhatariya, Ketan ^{[3
]}

Winocour, Peter ^{[4
]}

Gregory, Rob ^{[2
]}

机构：

[1] Conquest Hosp, Hastings, England

[2] Univ Hosp Leicester NHS Trust, Leicester, Leics, England

[3] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Norwich, Norfolk, England

[4] East & North Herts NHS Trust, Stevenage, Herts, England

来源：

BRITISH JOURNAL OF DIABETES | 2016年 / 16卷 / 04期

关键词：

SGLT-2; inhibitors; diabetic ketoacidosis; ABCD;

D O I：

10.15277/bjd.2016.112

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetic Ketoacidosis (DKA) has been reported in patients with diabetes taking SGLT-2 inhibitor drugs both in clinical trials and in real life situations, particularly amongst patients taking insulin. The US Food and Drug Administration (FDA) has issued a safety communication following 20 cases of DKA in patients receiving these drugs. 1 This concern has also prompted an American Association of Clinical Endocrinologists and American College of Endocrinology position statement covering the use of SGLT-2 inhibitors in people with type 2 diabetes. 2 The following is the ABCD position statement on this issue.

引用

页码：206 / +

页数：5

共 50 条

[1] Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)
Dashora, Umesh
Patel, Dipesh C.
Gregory, Robert
Winocour, Peter
Dhatariya, Ketan
Nagi, Dinesh
BRITISH JOURNAL OF DIABETES, 2019, 19 (01): : 66 - 72
[2] Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes
Dashora, Umesh
Patel, Dipesh
Gregory, Rob
Nagi, Dinesh
BRITISH JOURNAL OF DIABETES, 2018, 18 (03): : 117 - 121
[3] Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor
Zhang, Lydia
Tamilia, Michael
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (25) : E766 - E768
[4] Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis A Multicenter Cohort Study
Douros, Antonios
Lix, Lisa M.
Fralick, Michael
Dell'Aniello, Sophie
Shah, Baiju R.
Ronksley, Paul E.
Tremblay, Eric
Hu, Nianping
Alessi-Severini, Silvia
Fisher, Anat
Bugden, Shawn C.
Ernst, Pierre
Filion, Kristian B.
ANNALS OF INTERNAL MEDICINE, 2020, 173 (06) : 417 - +
[5] Prolonged Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Postmarketing Cases
Woronow, Daniel
Chamberlain, Christine
Houstoun, Monika
Munoz, Monica
ENDOCRINE PRACTICE, 2024, 30 (07) : 603 - 609
[6] Expanding Clinical Use of Sodium-glucose Cotransporter-2 Inhibitors?
Dhawan, Richa
Chaney, Mark A.
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2024, 38 (10) : 2135 - 2138
[7] Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis
Bloomgarden, Zachary T.
JOURNAL OF DIABETES, 2016, 8 (02) : 175 - 176
[8] Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020)
Dashora, Umesh
Patel, Dipesh C.
Gregory, Robert
Winocour, Peter
Dhatariya, Ketan
Rowles, Susannah
Macklin, Andrew
Rayman, Gerry
Nagi, Dinesh
DIABETIC MEDICINE, 2021, 38 (02)
[9] Sodium-glucose cotransporter-2 inhibitors in non-diabetic patients: is there a perioperative risk of euglycaemic ketoacidosis
Ruste, Martin
Schweizer, Remi
Groisne, Laure
Fellahi, Jean -Luc
Jacquet-Lagreze, Matthias
BRITISH JOURNAL OF ANAESTHESIA, 2024, 132 (02) : 435 - 436
[10] Case of sodium-glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis
Yeoh, Huei Li
Lee, Marilyn
Pan, Woei Jack
Ong, Hean Yee
BMJ CASE REPORTS, 2021, 14 (08)

← 1 2 3 4 5 →